69066-42-8

Basic information

• Product Name: 2-Oxo-2-[[4-(trifluoroMethyl)phenyl]aMino]acetic Acid
• Synonyms: 2-Oxo-2-[[4-(trifluoroMethyl)phenyl]aMino]acetic Acid;WFZYVQMWEBADID-UHFFFAOYSA-N
• CAS NO: 69066-42-8
• Molecular Formula: C₉H₆F₃NO₃
• Molecular Weight: 233.1440496
• Product Categories: Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 69066-42-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Oxo-2-[[4-(trifluoroMethyl)phenyl]aMino]acetic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxo-2-[[4-(trifluoroMethyl)phenyl]aMino]acetic Acid(69066-42-8)
• EPA Substance Registry System: 2-Oxo-2-[[4-(trifluoroMethyl)phenyl]aMino]acetic Acid(69066-42-8)

Safety Data

• Hazardous Substances Data: 69066-42-8(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 69066-42-8 differently. You can refer to the following data:
1. 2-Oxo-2-[[4-(trifluoromethyl)phenyl]amino]acetic Acid, can be use din the synthesis of Isocyanates, which are important class of organic compounds which have many applications in polymer chemistry (Polyurethanes), for herbicides, and crop-protecting agents.
2. 2-Oxo-2-[[4-(trifluoromethyl)phenyl]amino]acetic Acid, can be used in the synthesis of Isocyanates, which are important class of organic compounds which have many applications in polymer chemistry (Polyurethanes), for herbicides, and crop-protecting agents.

Upstream product

• 455-14-1 4-trifluoromethylphenylamine 
• 69066-00-8 ethyl 2-oxo-2-((4-(trifluoromethyl)phenyl)amino)acetate 

Relevant articles and documents

OXALAMIDE HETEROBYCYCLIC COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

CD4 mimics targeting the mechanism of HIV entry

A structure-activity relationship study was conducted of several CD4 mimicking small molecules which block the interaction between HIV-1 gp120 and CD4. These CD4 mimics induce a conformational change in gp120, exposing its co-receptor-binding site. This induces a highly synergistic interaction in the use in combination with a co-receptor CXCR4 antagonist and reveals a pronounced effect on the dynamic supramolecular mechanism of HIV-1 entry.